Does the Glycocalyx Explain the HRT Timing Hypothesis?

For more than two decades, we’ve wrestled with the Women’s Health Initiative.

Estrogen was supposed to protect the heart. Observational data suggested it did. Yet according to the data released by the WHI in 2002, hormone replacement therapy did not reduce the incidence of heart attacks. In some cases, it increased it. Conventional medicine apologized for its terrible mistake and quickly took HRT off the table for all but temporary relief of severe menopausal symptoms. 

Subsequent studies like the ELITE and KEEPS trials figured out that the WHI was measuring HRT’s efficacy in the wrong group of subjects – mostly postmenopausal women in their early sixties and older. When they analyzed the results in younger menopausal women, that’s when the HRT’s cardiovascular benefits were unmasked, just what you’d expect, given estrogen’s cardioprotective effect in premenopausal women.

This now widely accepted reinterpretation of the WHI data was dubbed “the timing hypothesis.” Theories were put forward to explain how it came to be that replacing estrogen was effective at 51 but ineffective, or risky, at 63, mostly having to do with the health of the inner lining of the coronary blood vessels, the endothelium. At an older age, the changes associated with atherosclerosis – more coronary plaque, higher levels of inflammation and an increased risk of thrombosis – were too far advanced, it was surmised, for HRT to turn back the endothelial clock.

But I’m persuaded this is only a partial explanation. I think we’re overlooking the role of a nearly invisible structure within the cardiovascular system – hard to image, hard to study – that most people have never heard of, that most physicians have barely heard of. That’s the endothelial glycocalyx (EG). As I wrote in my previous post, the EG is a gel-like mesh that lies between the endothelium and the blood that flows through it. (The blood doesn’t actually touch the endothelium, rather it flows through this mesh, made up mostly of complex sugars.)

A growing research literature has persuaded me that the glycocalyx may be the first domino to fall in an atherosclerotic progression that results in the development of plaque inside the coronary arteries and down the line, heart disease, heart attack or heart failure, and finally, death. And that much of the beneficial effect that estrogen has on the cardiovascular system derives less from tamping down LDL, the conventional explanation, and more from the hormone’s ability to protect the glycocalyx, allowing it to continue to protect the coronary vessels’ endothelium.

Let me explain.

It’s now well established that estrogen helps protect the coronary arteries by reducing systemic inflammation which, left unchecked, helps oxidize and “arm” the LDL particles inside the endothelium, setting them up to accrete into cholesterol plaque. (Many of my patients, and for that matter me, are on HRT and our arteries are relatively clear despite sometimes less than ideal LDL numbers. In the case of the men, some of the supplemental testosterone gets converted into estrogen, the hormone that actually provides the anti-inflammatory boost to the immune system.)

And recent research has established that the EG serves as a protective barrier for the endothelium, for instance, by regulating vascular permeability, limiting the amount of LDL that can enter the endothelium and helping to create a “no stick” surface that cholesterol, immune cells and platelets have a harder time latching on to and forming atherosclerotic plaques.

My hypothesis, that estrogen delivers its benefits to the cardiovascular system, at least in part, through the EG, can’t be definitely proven, or disproven, until we study the direct effects of estrogen on the EG. But there are some suggestive clues. The same cellular machinery responsible for the glycan complex sugars that help make up the glycocalyx mesh also produces the glycans that attach to circulating immune system proteins and help determine whether your immune system functions in a generally pro-inflammatory or anti-inflammatory fashion. In my practice, using the GlycanAge panel that measures these patterns in a single immune system antibody, IgG, I’ve seen my patients’ “immune age” drop twenty or thirty years after they’ve gone on HRT. It’s not a huge leap to imagine estrogen conferring a similar benefit to the glycans that make up the glycocalyx. Time, and more research, will tell.

But there are some relevant studies at hand. A 2023 review by a Brazilian team, “Female Hormones and the Endothelial Glycocalyx” synthesized experimental and translational data to demonstrate that female sex hormones – particularly estradiol – can affect EG structure and function through a variety of mechanisms, all of which could influence the course of cardiovascular health and illness. A 2025 study out of the University of Iowa found that the EG of postmenopausal women was thinner than male age-matched controls. 

As laid out in detail in a 2023 review, “Endothelial Glycocalyx Turnover in Vascular Health and Disease: Rethinking Endothelial Dysfunction,” the EG exists in a state of constant flux, its mesh structure continually breaking down and being built back up. To prove that HRT supported cardiovascular health via the EG we would need to demonstrate that added estrogen enhances the stability of that mesh. Here we don’t have proof but we do have biological plausibility on our side. We know that estrogen reduces oxidative stress, in theory, reducing the damage done to the molecular building blocks of the mesh, the glycosaminoglycan chains. It suppresses inflammatory cytokine signaling, which would otherwise activate protein-cleaving enzymes known as “sheddases” (such as metalloproteinases) that drive the breakdown, or “shedding,” process

If HRT allows us to preserve EG structure deeper into our senior years, so much the better for our cardiovascular systems. A healthy EG not only protects the endothelium from the buildup of cholesterol plaque, it also acts as a sensor, operating as a kind of interface between blood and blood vessel. It registers the mechanical shear forces produced by blood flow on the vessels and cues the endothelial cells to produce more nitric oxide. That smooths out blood flow and allows the resulting pressure wave to return to the heart more slowly, reducing the wear and tear on the coronary vessels, as well as on the capillaries that feed the kidneys and brain, and on the heart muscle itself.

It's this proposed connection between estrogen levels, EG structure and cardiovascular health that allows us to make better sense of the HRT “timing hypothesis.” HRT given during menopause may be able to reverse some of the early damage to the mesh layer caused by inflammation and oxidative stress. A decade or so beyond menopause, the damage may have become so entrenched as to be irreversible. A now-thinned-out mesh no longer protects the endothelial lining or cues nitric oxide at the appropriate time and adding estrogen won’t make any difference. In fact, at this stage, HRT may become harmful in susceptible individuals, as that WHI data indicated. The oral HRT used in the WHI can increase blood clotting and the risk of thrombosis, a risk adequately mitigated by a healthy EG, but not by a degraded one. (All that said, I do give HRT to older female patients whose coronaries test out as relatively clear but I go slow and complement with statin therapy if their lipids are suboptimal.)

I suspect our growing understanding of the endothelial glycocalyx will reframe menopause not merely as a hormonal transition, but as a tipping point in vascular resilience. The question is not simply whether estrogen lowers LDL or calms inflammation. At a deeper level it’s:  “Does estrogen preserve the structural interface that allows arteries to sense stress, repair damage, and resist plaque formation in the first place?” From that perspective, HRT is not about symptom relief. It’s about preserving repair capacity and protecting one of the most critical components of the arterial system. And that is why I believe every woman, absent clear contraindications, should at least be offered the opportunity to use it.

---

Potje SR, Martins NS, Benatti MN, Rodrigues D, Bonato VLD, Tostes RC. The effects of female sex hormones on the endothelial glycocalyx. Curr Top Membr. 2023;91:89-137. doi:10.1016/bs.ctm.2023.02.005 

Gimblet CJ, Donato AJ, Jalal DI, Pierce GL. Sex differences in endothelial glycocalyx thickness and the response to glycocalyx-targeted therapy among older adults. Physiol Rep. 2025;13(12):e70428. doi:10.14814/phy2.70428

Gomez Toledo A, et al. Endothelial glycocalyx turnover in vascular health and disease: rethinking endothelial dysfunction. Annu Rev Biochem. 2025;94:561-586. doi.org/10.1146/annurev-biochem-032620-104745.

Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.  doi:10.1056/NEJMoa15052411.

Miller VM, Taylor HS, Naftolin F, et al. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2021;24(2):139-145. doi:10.1080/13697137.2020.1804545.